AUTHOR=Ghorbani Mahin , Al-Manei Khaled , Naud Sabrina , Healy Katie , Gabarrini Giorgio , Sobkowiak Michal Jacek , Chen Puran , Ray Shilpa , Akber Mira , Muschiol Sandra , Bogdanovic Gordana , Bergman Peter , Ljungman Per , Buggert Marcus , Ljunggren Hans-Gustaf , Pin Elisa , Nowak Piotr , Aleman Soo , Sällberg Chen Margaret TITLE=Persistence of salivary antibody responses after COVID-19 vaccination is associated with oral microbiome variation in both healthy and people living with HIV JOURNAL=Frontiers in Immunology VOLUME=13 YEAR=2023 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1079995 DOI=10.3389/fimmu.2022.1079995 ISSN=1664-3224 ABSTRACT=
Coevolution of microbiome and immunity at mucosal sites is essential for our health. Whether the oral microbiome, the second largest community after the gut, contributes to the immunogenicity of COVID-19 vaccines is not known. We investigated the baseline oral microbiome in individuals in the COVAXID clinical trial receiving the BNT162b2 mRNA vaccine. Participants (n=115) included healthy controls (HC; n=57) and people living with HIV (PLHIV; n=58) who met the study selection criteria. Vaccine-induced Spike antibodies in saliva and serum from 0 to 6 months were assessed and comparative analyses were performed against the individual salivary 16S ASV microbiome diversity. High- versus low vaccine responders were assessed on general, immunological, and oral microbiome features. Our analyses identified oral microbiome features enriched in high-